Influence of sex differences on the pharmacokinetics of tilidine and its metabolites nortilidine in healthy Chinese volunteers

doi:10.5246/jcps.2012.01.013

• 【Short communications】 • Previous Articles Next Articles

Influence of sex differences on the pharmacokinetics of tilidine and its metabolites nortilidine in healthy Chinese volunteers

Li Sun , Xiao-Xiao Li , Hua-Ying Fan, Jun-Cheng Liang, Yan-Ping Deng^*

National Institute on Drug Dependence, Peking University, Beijing 100191, China

Received:2011-05-10 Revised:2011-09-10 Online:2012-01-01 Published:2012-01-01
Contact: Yan-Ping Deng*

Abstract

Abstract:

This study was conducted to assess the pharmacokinetic characteristics of tilidine and its active metabolites nortilidine in healthy Chinese male and female volunteers. Nine healthy volunteers (4 male and 5 female) were included in the study. Subjects were administered a single oral dose 50 mg tilidine hydrochloride oral solution. The plasma tilidine and nortilidine concentrations were determined by gas chromatography nitrogen phosphorous detection (GC-NPD). The pharmacokinetic parameters were estimated from plasma concentration-time profiles using model independent method. The main pharmacokinetic data (mean±SD) for tilidine and nortilidine were Cmax (63.39±28.99) and (122.53±23.23) ng/mL; Tmax (0.37±0.07) and (0.64±0.30) h; t1/2(2.83±1.35) and (5.72±1.37) h; AUC0-∞ (101.59±41.85) and (577.13±189.77) ng·h/mL, respectively. The mean pharmacokinetic parameters for male and female were as follows: for tilidine: Cmax (73.88±40.88) and (55.01±15.16) ng/mL, Tmax (0.37±0.08) and (0.36±0.08) h, t1/2(4.05±1.07) and (1.86±0.41) h, AUC0-∞ (119.00±55.11) and (87.66±26.08) ng·h/mL; for nortilidine: Cmax (108.82±27.88) and (133.49±12.56) ng/mL, Tmax (0.94±0.13) and (0.40±0.09) h, t1/2(4.66±1.18) and (6.57±0.84) h, AUC0-∞ (601.59±281.07) and (557.57±108.16) ng·h/mL. The t1/2 for tilidine in male was significantly higher than that in female, while Tmax for nortilidine in male was significantly higher than that in female. There was no serious adverse effects, but significant difference in the incidence of adverse effects was found between male and female. There was no sufficient pharmacokinetic reason to adjust the dose of tilidine when it was administered in Chinese patients.

CLC Number:

R969.1

Supporting:

Li Sun , Xiao-Xiao Li , Hua-Ying Fan, Jun-Cheng Liang, Yan-Ping Deng^*. Influence of sex differences on the pharmacokinetics of tilidine and its metabolites nortilidine in healthy Chinese volunteers [J]. , DOI: 10.5246/jcps.2012.01.013.

References

[1] Hajda, J.P.; Jähnchen, E.; Oie, S.; Trenk, D. J. Clin. Pharmacol. 2002, 42, 1257-1261.
[2] Seiler, K.U.; Jähnchen, E.; Trenk, D.; Brennscheidt, U.; Heintz, B. J. Clin. Pharmacol. 2001, 41, 79-84.
[3] Regenthal, R.; Krüger, M.; Richter, M.; Preiss, R. Hum. Exp. Toxicol. 1998, 17, 593-597.
[4] Brennscheidt, U.; Seiler, K.U.; Thomann, P. Arzneimittelforschung. 2000, 50, 1015-1022.
[5] Dubinsky, B.; Crew, M.C.; Melgar, M.D.; Karpowicz, J.K.; Di Carlo, F.J. Biochem. Pharmacol. 1975, 24, 277-281.
[6] Schulz, R.; Bläsig, J.; Wüster, M.; Herz, A. Naunyn Schmiedebergs Arch. Pharmacol. 1978, 304, 89-93.
[7] Thierry, C.; Boeynaems, J.M.; Paolo, M. Eur. J. Pharmacol. 2005, 506, 205-208.
[8] Weiss, J.; Sawa, E.; Riedel, K.D.; Haefeli, W.E.; Mikus, G. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 378, 275-282.
[9] Xie, H.G.; Kim, R.B.; Wood, A.J.; Stein, C.M. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 815-850.
[10] Xie, H.G.; Stein, C.M.; Kim, R.B.; Wilkinson, G.R.; Flockhart, D.A.; Wood, A.J. Pharmacogenetics. 1999, 9, 539-549.
[11] Hunt, C.M.; Westerkam, W.R.; Stave, G.M. Biochem. Pharmacol. 1992, 44, 275-283.
[12] Hooper, W.D.; Qing, M.S. Clin. Pharmacol. Ther. 1990, 48, 633-640.
[13] Roth, M.E.; Cosgrove, K.P.; Carroll, M.E. Neurosci. Biobehav. Rev. 2004, 28, 533-546.
[14] Hengy, H.; Vollmer, K.O.; Gladigau, V. J. Pharm. Sci. 1978, 67, 1765-1768.
[15] Cordonnier, J.; Wauters, A.; Heyndrickx, A. J. Anal. Toxicol. 1987, 11, 144-148.
[16] Martin, W.; Ring, J.; Gaupp, M.; Arnold, P.; Sennewald, R.; Doser, K. Arzneimittelforschung. 1999, 49, 599-607.
[17] Vollmer, K.O.; Thomann, P.; Hengy, H. Arzneimittelforschung. 1989, 39, 1283-1288.
[18] Westlind, A.; Löfberg, L.; Tindberg, N.; Andersson, T.B.; Ingelman-Sundberg, M. Biochem. Biophys. Res. Commun. 1999, 259, 201-205.
[19] Ozdemir, V.; Kalow, W.; Tang, B.K.; Paterson, A.D.; Walker, S.E.; Endrenyi, L.; Kashuba, A.D. Pharmacogenetics. 2000, 10, 373-388.

Influence of sex differences on the pharmacokinetics of tilidine and its metabolites nortilidine in healthy Chinese volunteers

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 3

Recommended Articles

Metrics

Comments

[1]	Rui-Rui Zhang, Xiao-Hui Chen, Qing Li, Wen-Tao Liu, Wen-Wen Yang, Kai-Shun Bi, Li-Xin Sun^*. Liquid chromatography coupled with mass spectrometry method for the simultaneous quantification of irbesartan and hydrochlorothiazide in human plasma [J]. , 2011, 20(4): 360-367.
[2]	Li-Hui Wang^1,2, Hui-Hui Zeng^1,2* . Investigation of the redox status in H22 hepatocellular carcinoma xenografts treated by a novel anticancer drug——ethaselen [J]. , 2009, 18(3): 245-251.
[3]	Hai-Yan Xu, Peng Zhang, Xue-Ya Wang, Tao Shen, Huai-Qing Zhao^*. Pharmacokinetics and bioequivalence of two pantoprazole sodium enteric-coated tablet products in healthy Chinese volunteers [J]. , 2007, 16(3): 170-175.